Articles with public access mandates - Don SiegelLearn more
Not available anywhere: 5
Translational applications of antibody phage display
DL Siegel
Immunologic research 42, 118-131, 2008
Mandates: US National Institutes of Health
Targeted in vivo loading of red blood cells markedly prolongs nanocarrier circulation
PM Glassman, CH Villa, OA Marcos-Contreras, ED Hood, LR Walsh, ...
Bioconjugate Chemistry 33 (7), 1286-1294, 2022
Mandates: US National Institutes of Health
Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells)
J Xu, M Gohil, E Stadtmauer, JA Fraietta, VE Gonzalez, J Salas-McKee, ...
Cytotherapy 22 (5), S35-S36, 2020
Mandates: US National Institutes of Health
FLOW CYTOMETRY CASE STUDIES ILLUSTRATING COMPREHENSIVE APPROACH REQUIRED FOR DEVELOPING, OPTIMIZING, AND IMPLEMENTING MULTICOLOR PANELS FOR THE MANUFACTURING AND RELEASE OF …
S Mackey, A Dai, MM Davis, A Fesnak, D Siegel, G Plesa
Cytotherapy 26 (6), S137-S138, 2024
Mandates: UK Research & Innovation
Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products
W Gladney, E Hexner, J Salas-McKee, A Fesnak, J Jadlowsky, G Plesa, ...
Cytotherapy 22 (5), S35, 2020
Mandates: US National Institutes of Health
Available somewhere: 64
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
JA Fraietta, SF Lacey, EJ Orlando, I Pruteanu-Malinici, M Gohil, S Lundh, ...
Nature medicine 24 (5), 563-571, 2018
Mandates: US National Institutes of Health
CRISPR-engineered T cells in patients with refractory cancer
EA Stadtmauer, JA Fraietta, MM Davis, AD Cohen, KL Weber, E Lancaster, ...
Science 367 (6481), eaba7365, 2020
Mandates: US National Science Foundation, US National Institutes of Health
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ...
Nature medicine 21 (8), 914-921, 2015
Mandates: US National Institutes of Health
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
AD Cohen, AL Garfall, EA Stadtmauer, JJ Melenhorst, SF Lacey, ...
The Journal of clinical investigation 129 (6), 2210-2221, 2019
Mandates: US National Institutes of Health
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
JJ Melenhorst, GM Chen, M Wang, DL Porter, C Chen, MKA Collins, ...
Nature 602 (7897), 503-509, 2022
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey, AJ Rech, MM Davis, ...
Nature medicine 28 (4), 724-734, 2022
Mandates: US National Institutes of Health
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
AL Garfall, EA Stadtmauer, WT Hwang, SF Lacey, JJ Melenhorst, ...
JCI insight 3 (8), 2018
Mandates: US National Institutes of Health
Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors
L Wang, R Calcedo, P Bell, J Lin, RL Grant, DL Siegel, JM Wilson
Human gene therapy 22 (11), 1389-1401, 2011
Mandates: US National Institutes of Health
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
X He, Z Feng, J Ma, S Ling, Y Cao, B Gurung, Y Wu, BW Katona, ...
Blood, The Journal of the American Society of Hematology 135 (10), 713-723, 2020
Mandates: US National Institutes of Health
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
AL Garfall, EK Dancy, AD Cohen, WT Hwang, JA Fraietta, MM Davis, ...
Blood advances 3 (19), 2812-2815, 2019
Mandates: US National Institutes of Health
Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia
RM Myers, Y Li, A Barz Leahy, DM Barrett, DT Teachey, C Callahan, ...
Journal of Clinical Oncology 39 (27), 3044-3055, 2021
Mandates: US National Institutes of Health
Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study
JH Beigel, P Tebas, MC Elie-Turenne, E Bajwa, TE Bell, CB Cairns, ...
The Lancet Respiratory Medicine 5 (6), 500-511, 2017
Mandates: US Department of Defense, US National Institutes of Health
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
RL Olin, DT Vogl, DL Porter, SM Luger, SJ Schuster, DE Tsai, DL Siegel, ...
Bone marrow transplantation 43 (5), 417-422, 2009
Mandates: US National Institutes of Health
Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier
CH Villa, DC Pan, S Zaitsev, DB Cines, DL Siegel, VR Muzykantov
Therapeutic delivery 6 (7), 795-826, 2015
Mandates: US National Institutes of Health
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration
CL Nobles, S Sherrill-Mix, JK Everett, S Reddy, JA Fraietta, DL Porter, ...
The Journal of Clinical Investigation 130 (2), 673-685, 2020
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program